Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent metastatic gastroesophageal cancers

Circulating Tumor DNA as a Marker of Recurrence Risk in Locoregional Esophagogastric Cancers with Pathologic Complete Response

Feasibility and Dynamics of Preoperative Circulating Tumor DNA in Gastroesophageal Cancer Patients Receiving Preoperative Treatment

Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging center

Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib

Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer

Asco 2022 Monitoring Efficacy of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma

ASCO GU 2022 Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring

Serial postoperative ctDNA monitoring of breast cancer recurrence

Comparison of the predictive and prognostic significance of circulating tumor DNA

Personalized Circulating tumor DNA as a Predictive Biomarker in High-Risk Early Stage Breast Cancer Treated With Neoadjuvant Chemotherapy

Circulating tumor DNA predicts disease recurrence in ovarian cancer patients

Comparison of the Predictive and Prognostic Significance of Circulating Tumor DNA in Patients with High Risk HER2-negative Breast Cancer

ASCO 2022 mRCC: ctDNA testing before and after treatment with sunitinib

Tumor-informed assessment of molecular residual disease

Kasi PM, Dayyani F, Morris V. Poster presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4108.

Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer ESMP 2018

Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response and/or detect disease recurrence earlier.

Sequencing of plasma cfDNA from patients with locally advanced bladder cancer AACR 2018

Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response to neoadjuvant therapy.

Presence of Circulating Tumor DNA in Surgically Resected Renal Cell Carcinoma ESMO 2020

Circulating tumor DNA (ctDNA) has emerged as a promising, non-invasive biomarker for preclinical detection and monitoring of various cancers.

Personalized circulating tumor DNA analysis to monitor colorectal cancer AACR 2018

Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).

Characterization of Clonal Hematopoiesis of Indeterminate Potential Mutations from Germline